Five things for pharma marketers to know: Tuesday, April 24, 2018

Share this content:

Express Scripts is pressuring Amgen against setting a high list price for its new migraine medicine. The move is being seen as an attempt to transfer blame from PBMs, who have been accused of keeping rebates for themselves, to manufacturers, who continue to raise list prices. (Reuters)


Takeda has made a fifth offer to acquire Shire. (MarketWatch) The two companies are on the brink of reaching a preliminary deal, which would value Shire at more than $60 billion. An announcement could take place as early as today. (Bloomberg)


Sandoz has partnered with Pear Therapeutics to launch the company's FDA-approved apps for treating patients with substance use disorder. The pharma manufacturer will provide a dedicated sales team for Pear's products. (MM&M)


AstraZeneca's Imfinzi and tremelimumab combo therapy to fight lung cancer failed to beat chemotherapy at slowing the disease's progression or improving overall survival. Recent findings suggest that adding chemotherapy to immunotherapy, rather than combining two immunotherapies, as the AstraZeneca trial did, produces better results. (Reuters)


Sanofi's R&D head is stepping down. Elias Zerhouni, former director of the National Institute of Health, will hand the reins to John Reed, who has run a research group for Roche for the past five years. (Endpoints)


Share this content:
Scroll down to see the next article